I agree with a lot of your arguments particularly with the shift...

I agree with a lot of your arguments particularly with the shift to CY 2018 from FY2018 and outcome (expenditure/cost) not matching his claims in the presentation. In some of these situations, like wages growth when you are trying to grow the company, it can be somewhat unavoidable.
However shifts in comparison periods are done by almost all ASX companies and perhaps u are being a little harsh here.........
What I have most difficulty with is your sentiment of sell . This is a little odd. Is this a case of throwing the baby out with the bath water ? you can distrust the CEO but you can hardly argue with peer reviewed scientific papers about the superiority of ADAPT which gives AHZ a blue sky prospect most ASX companies can only dream off, yes there are bumps on the way but that's how bicotech are...........